86 related articles for article (PubMed ID: 18306910)
1. Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation.
Urso R; Nencini C; Giorgi G; Fiaschi AI
Eur Rev Med Pharmacol Sci; 2007; 11(6):413-7. PubMed ID: 18306910
[TBL] [Abstract][Full Text] [Related]
2. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
3. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
4. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
5. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
[TBL] [Abstract][Full Text] [Related]
6. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
Wallin JE; Friberg LE; Karlsson MO
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):234-42. PubMed ID: 20050841
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
9. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
[TBL] [Abstract][Full Text] [Related]
10. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
[TBL] [Abstract][Full Text] [Related]
11. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
12. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
14. Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
Würthwein G; Boos J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):303-8. PubMed ID: 11914910
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of potential interaction between vinorelbine and clarithromycin.
Yano R; Tani D; Watanabe K; Tsukamoto H; Igarashi T; Nakamura T; Masada M
Ann Pharmacother; 2009 Mar; 43(3):453-8. PubMed ID: 19261952
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
[TBL] [Abstract][Full Text] [Related]
18. Can similar oral blood exposures between studies result in a different bioavailability?
Puozzo C
Cancer Chemother Pharmacol; 2006 Dec; 58(6):838-41. PubMed ID: 16557414
[No Abstract] [Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]